| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2006 | CA2574193A1 Benzothiazole derivatives as adenosine receptor ligands |
| 01/26/2006 | CA2574188A1 Anti-histaminic composition |
| 01/26/2006 | CA2574180A1 Substituted benzothiazoles |
| 01/26/2006 | CA2574162A1 Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase 1b (ptp1b) inhibitors for using as blood-sugar decreasing active ingredients for treating diabetes |
| 01/26/2006 | CA2574135A1 Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
| 01/26/2006 | CA2574060A1 Immune modulating compounds from fungi |
| 01/26/2006 | CA2574006A1 Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| 01/26/2006 | CA2573985A1 A pharmaceutical composition comprising gabapentin |
| 01/26/2006 | CA2573969A1 Oxidative degradation products of atorvastatin calcium |
| 01/26/2006 | CA2573943A1 6-formyltetrahydropteridines method for production and use thereof as medicament against cancer amongst other things |
| 01/26/2006 | CA2573915A1 Preventive and/or therapeutic agent for sleeping disorder |
| 01/26/2006 | CA2573718A1 Hair growth promoting agents |
| 01/26/2006 | CA2573674A1 Muscarinic antagonists with parp and sir modulating activity as agents for inflammatory diseases |
| 01/26/2006 | CA2573673A1 Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
| 01/26/2006 | CA2573494A1 Control of biofilm formation |
| 01/26/2006 | CA2573393A1 Combinations of statins with bronchodilators |
| 01/26/2006 | CA2573210A1 Viral polymerase inhibitors |
| 01/26/2006 | CA2573190A1 Mt477 and related compounds for the treatment of various cancers |
| 01/26/2006 | CA2572822A1 Dimeric piperidine derivatives |
| 01/26/2006 | CA2572821A1 Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders |
| 01/26/2006 | CA2572819A1 Methylidene-d-xylopyranosyl-substituted and oxo-d-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and method for the production thereof |
| 01/26/2006 | CA2572796A1 Lipid-amino acid conjugates and methods of use |
| 01/26/2006 | CA2572793A1 Progression inhibitor for disease attributed to abnormal accumulation of liver fat |
| 01/26/2006 | CA2572735A1 Novel compounds that inhibit factor xa activity |
| 01/26/2006 | CA2572047A1 Octahydropyrrolo[2,3,c]pyridine derivatives and pharmaceutical use thereof |
| 01/26/2006 | CA2571884A1 Hyaluronic acid in the enhancement of lens regeneration |
| 01/26/2006 | CA2571881A1 Heterocyclic derivatives for modulation of calcium channels |
| 01/26/2006 | CA2571552A1 Compositions comprising 5-alpha reductase inhibitors, and serms and methods of use thereof |
| 01/26/2006 | CA2571457A1 Cancer chemotherapy |
| 01/26/2006 | CA2571242A1 Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior |
| 01/26/2006 | CA2571001A1 Methods for treating or preventing erectile dysfunction or urinary incontinence |
| 01/26/2006 | CA2570999A1 Compounds, compositions and methods |
| 01/26/2006 | CA2570968A1 Gonadotropin releasing hormone receptor antagonists |
| 01/26/2006 | CA2570916A1 Pulsed release dosage form of a ppi |
| 01/26/2006 | CA2570887A1 Tumor treatment |
| 01/26/2006 | CA2570825A1 Use of a steroid for enhancement of skin permeability |
| 01/26/2006 | CA2570817A1 Azaindoles modulating c-kit activity and uses therefor |
| 01/26/2006 | CA2570800A1 Processes for preparing 6-alkyl-5-arylsulfonyl- dihydrophenanthridines |
| 01/26/2006 | CA2570782A1 Peripherally-acting vasodilators |
| 01/26/2006 | CA2570780A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 01/26/2006 | CA2570698A1 Bis(thio-hydrazide amide) salts for treatment of cancers |
| 01/26/2006 | CA2570693A1 Processes for preparing gonadotropin releasing hormone receptor antagonists |
| 01/26/2006 | CA2570433A1 Medicaments for inhalation comprising pde iv inhibitors and enantiomerically pure glycopyrrolate salts |
| 01/26/2006 | CA2569015A1 Modified release formulation of memantine |
| 01/26/2006 | CA2568753A1 Use of a pharmaceutical composition comprising calcitriol and clobetasol propionate for the treatment of psoriasis |
| 01/26/2006 | CA2567569A1 Selective inhibitors against cdk4 and cdk6 having aminothiazole skeleton |
| 01/26/2006 | CA2553065A1 New pharmaceutical compositions based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins |
| 01/26/2006 | CA2513080A1 Inhibitors of the anandamide transporter |
| 01/25/2006 | EP1619373A1 Internal combustion engine control device |
| 01/25/2006 | EP1619250A1 WSX receptor and ligands |
| 01/25/2006 | EP1619249A1 Induction of exon skipping in eukaryotic cells |
| 01/25/2006 | EP1619244A1 Method for inducing neural differentiation |
| 01/25/2006 | EP1619210A1 DDS compounds and method for assaying the same |
| 01/25/2006 | EP1619197A1 Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)diones and -4(3H)ones as well as Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)diones und -4(3H)ones as inhibitors of TNF-alpha release |
| 01/25/2006 | EP1619196A1 Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release |
| 01/25/2006 | EP1619195A2 Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same |
| 01/25/2006 | EP1619194A2 Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient |
| 01/25/2006 | EP1619193A1 Spiropiperidine compound and medicinal use thereof |
| 01/25/2006 | EP1619192A2 Aryl fused azapolycyclic compounds |
| 01/25/2006 | EP1619189A1 N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives |
| 01/25/2006 | EP1619188A1 Process for the preparation of monoaryl piperazines |
| 01/25/2006 | EP1619182A1 Substance exhibiting antidepressant property |
| 01/25/2006 | EP1618897A1 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 01/25/2006 | EP1618895A1 Composition containing medicine extremely slightly soluble in water and method for preparation thereof |
| 01/25/2006 | EP1618894A1 Composition for injection |
| 01/25/2006 | EP1618893A1 Sugar intake-ability enhancer |
| 01/25/2006 | EP1618885A1 Cosmetic and/or pharmaceutical compositions containing fatty acids and extracts of castanea sativa |
| 01/25/2006 | EP1618883A1 Agent for preventing and ameliorating constipation |
| 01/25/2006 | EP1618882A2 Estrogen compositions for neuroprotection |
| 01/25/2006 | EP1618881A1 Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
| 01/25/2006 | EP1618880A1 Use of compounds derived from 2,3-dehydronaringenin for the treatment of inflammatory processes and pharmaceutical composition containing said derivatives |
| 01/25/2006 | EP1618879A1 Injectable formulations of taxanes for cad treatment |
| 01/25/2006 | EP1618878A1 Body-temperature lowering depressant |
| 01/25/2006 | EP1618876A1 Use of sphingolipids for prevention and treatment of atherosclerosis |
| 01/25/2006 | EP1618875A1 Composition for inhibition or prevention of bone density lowering and refreshment therefor |
| 01/25/2006 | EP1618874A2 Prevention of hiv-1 infection by inhibition of rho-mediated reorganisation and/or content alteration of cell membrane raft domains |
| 01/25/2006 | EP1618873A1 Granule for the control release of tamsulosin, containing alginate |
| 01/25/2006 | EP1618205A2 Methods of treating diseases responsive to induction of apoptosis and screening assays |
| 01/25/2006 | EP1618203A2 Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade |
| 01/25/2006 | EP1618120A2 Novel ketolide derivatives |
| 01/25/2006 | EP1618117A1 Tumor selective and biodegradable polyphosphazene-platinum(ii) conjugate antitumor agent, and preparation method thereof |
| 01/25/2006 | EP1618109A2 Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
| 01/25/2006 | EP1618108A2 Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists |
| 01/25/2006 | EP1618106A2 Carbacephem -lactam antibiotics |
| 01/25/2006 | EP1618103A2 Polymorphs of aripiprazole |
| 01/25/2006 | EP1618099A2 Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| 01/25/2006 | EP1618098A2 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| 01/25/2006 | EP1618093A2 Indazole derivatives as jnk inhibitors |
| 01/25/2006 | EP1618092A1 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
| 01/25/2006 | EP1618091A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| 01/25/2006 | EP1618090A1 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| 01/25/2006 | EP1618087A2 Antibacterial agents |
| 01/25/2006 | EP1618086A2 Compounds for the treatment of metabolic disorders |
| 01/25/2006 | EP1618085A1 Preparation method of conjugated linoleic acid diglycerides |
| 01/25/2006 | EP1617873A2 Mitomycin conjugates cleavable by thiols |
| 01/25/2006 | EP1617859A1 Methods and compositions using gonadotropin hormone releasing hormone |
| 01/25/2006 | EP1617853A1 Isolation of the hepatoprotective agent acteoside from colerbrokea oppositifolia |
| 01/25/2006 | EP1617849A1 Composition and uses of galectin antagonists |
| 01/25/2006 | EP1617848A2 Anti-cancer phosphonate conjugates |
| 01/25/2006 | EP1617847A2 Methods for the controlled delivery of pharmacologically active compounds |